SAFER TRAVELLER'S DIARRHEA DRUG

12 April 1992

A safer treatment for traveller's diarrhea may soon be available, which will be suitable for use by adults, children and pregnant women, according to a study published in the Journal of the American Medical Association.

The treatment takes the form of oral aztreonam, a poorly-absorbed antibiotic which, according to Herbert DuPont and colleagues of the Center for Infectious Diseases, University of Texas Medical School, "was well-tolerated and was an effective therapy for bacterial diarrhea in US adults in Mexico."

Currently available treatments for bacterial diarrhea have disadvantages, state the authors, including increasing rates of bacterial resistance, contraindications in children and pregnant women and a general lack of efficacy against the common enteropathogens.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight